We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Liquid Biopsy Test Tracks Treatment-Based ctDNA Changes

By LabMedica International staff writers
Posted on 06 Oct 2021
Print article
Image: Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. The LiquidHALLMARK assay, a liquid biopsy test, tracks treatment-based ctDNA changes (Photo courtesy of Jonathan Bailey, National Human Genome Research Institute)
Image: Circulating tumor DNA (ctDNA) is found in the bloodstream and refers to DNA that comes from cancerous cells and tumors. The LiquidHALLMARK assay, a liquid biopsy test, tracks treatment-based ctDNA changes (Photo courtesy of Jonathan Bailey, National Human Genome Research Institute)
Metastatic or unresectable disease is identified in approximately 20% of patients presenting with invasive urothelial cancer. In addition, up to 50% of patients will develop metastases following radical cystectomy for clinically localized disease.

Multiagent cisplatin-based chemotherapy is considered standard first-line treatment for these patients. Although urothelial cancer is considered a chemosensitive tumor, metastatic disease is associated with poor prognosis and short-term survival.

Medical Scientists collaborating with those at the Dana-Farber Cancer Institute (Boston, MA, USA) followed 45 participants with metastatic urothelial carcinoma, or mUC, 39 of who underwent immune checkpoint inhibitor, or ICI, therapy while six received cisplatin-based chemotherapy. The median age was 68 years, 79% of patients were male, and 97% had urothelial histology. The majority (82%) received single-agent ICI (PD1/L1 inhibitor). Median duration between pre and post samples was 6.2 months.

Investigators collected plasma samples before therapy and about six months afterwards, then correlated changes in circulating tumor DNA (ctDNA) with objective response using the LiquidHALLMARK assay (Lucence, Palo Alto, CA, USA). Paired pre and post samples underwent ctDNA evaluation with 7 to 30 ng of DNA using an 80-gene panel which employs an amplicon-based NGS assay, including fusions (Lucence, LiquidHALLMARK). The primary objective was to evaluate ctDNA alterations pre- and post-ICI, and to correlate with objective response.

The investigators reported that the most common variants pre- and post-ICI were in TP53 (54% and 49%), TERT (49% and 49%) and BRCA1/2 (36% and 33%). Nine patients were responding to ICI at time of post-ICI blood collection, with seven (78%) showing clearance of ≥1 ctDNA variants, most commonly in TP53, PI3KCA, and BRCA1/2. In 18/20 patients (90%) who were progressing at time of post-ICI collection had emergence of a new alteration, most commonly in BRCA1/2, PI3KCA, CCND2/RB, and TP53. BRCA1 and PIK3CA mutations emerged in only one and zero chemo patients. Patients who cleared TP53 alterations during ICI had a higher likelihood of response compared to those who did not (50% versus 17%).

Guru Sonpavde, MD, a Medical Oncologist and the principal investigator said, “This is somewhat impressive because in most ctDNA platforms, there is not such a high percentage of patients where you see ctDNA alterations.”

The authors concluded that ctDNA alterations were detected in 96% of pre/post-ICI samples overall. Clearance of TP53 alterations during ICI therapy was associated with response, while emergence of BRCA1/2 or PI3KCA variants appeared to be associated with resistance. The study was presented at the European Society for Medical Oncology Virtual Congress held September 16-21, 2021.

Related Links:
Dana-Farber Cancer Institute
Lucence


Gold Supplier
Blood Glucose Laboratory Analyzer
Nova Primary
New
Real Time PCR Platform
VIASURE V-Lab96
New
Laboratory Water System
Q-CHE40-SR/Q-CHE80-SR
New
Silver Supplier
Automated RPR Syphilis Test
Automated RPR Test Kit

Print article

Channels

Hematology

view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.